Synthetic somatostatin analogues in cures of bleeding from esophageal varices

Cover Page

Abstract


The study of clinical effectiveness of synthetic somatostatin analogues in prophylaxis of bleeding from esophageal varices was conducted. There were 129 patients (mean age 45,2 ± 16,3) with previous or continuous bleeding from oesophageal varices included in the study, 65 of whom received synthetic somatostatin analogues (sandostatin and octreotide) therapy. Synthetic somatostatin analogues were administered as intravenous bolus injection in 100 μg dose, followed by continuous intravenous infusion at a rate of 25 μg/h for 2 days. From day 3, medication was given subcutaneously, 300 μg per day for another 3 days. The pressure in the portal system was measured with endoscopic tensometry in order to assess the effectiveness of somatostatin analogues. There was a tendency for portal pressure to decrease with a mean value being 33%. Synthetic somatostatin analogues are effective means of therapeutic haemostasis, preventing the recurrence of bleeding from oesophageal varices with haemostatic effect being above 85%.

A A Schyogolev

Russian national medical university

Email: 3664658@mail.ru
Кафедра хирургических болезнейМосковский факультет; Российский государственный медицинский университет; Russian national medical university

O A Alsabunchi

Russian national medical university

Email: 3664658@mail.ru
Кафедра хирургических болезнейМосковский факультет; Российский государственный медицинский университет; Russian national medical university

S A Valetov

Russian national medical university

Email: 3664658@mail.ru
Кафедра хирургических болезнейМосковский факультет; Российский государственный медицинский университет; Russian national medical university

R R Mudarisov

Clinical hospital № 36

Email: docmr@rambler.ru
Clinical hospital № 36

Views

Abstract - 26

PDF (Russian) - 152


Copyright (c) 2010 Щеголев А.А., Аль-Сабунчи О.А., Валетов С.А., Мударисов Р.Р.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.